We are live on ! Find out more
10.46 USD
+0.19
1.85%
At close Updated Sep 8, 4:00 PM EDT
1 day
1.85%
5 days
-0.38%
1 month
0.1%
3 months
3.56%
6 months
-7.43%
Year to date
-27.16%
1 year
-8.33%
5 years
-5.85%
10 years
19.68%
 

About: Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. The company operates as a single business segment centered on the development, commercialization, and support of its proprietary blood volume analysis technology used by healthcare providers.

Employees: 750

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 0%
Neutral 100%
Negative 0%
Neutral
GlobeNewsWire
2 hours ago
Daxor Corporation to Participate in the 10th Annual Lake Street Best Ideas Growth Conference
Oak Ridge, TN, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will participate in Lake Street's Tenth Annual Best Ideas Growth (BIG10) Conference in New York City, New York on Thursday, September 10th, 2026.
Daxor Corporation to Participate in the 10th Annual Lake Street Best Ideas Growth Conference
Neutral
GlobeNewsWire
7 days ago
Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter
Oak Ridge, TN, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today provides a mid-year corporate and financial update in a Letter to Shareholders from CEO and President Michael Feldschuh.
Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter
Neutral
GlobeNewsWire
1 month ago
Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas
Commercial Momentum Accelerates as Health System Adopts Turnkey Blood Volume Analysis via CLIA-Certified Send-Out Model OAK RIDGE, TN, July 29, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced the launch of a new outpatient Blood Volume Analysis (BVA™) program at a leading healthcare facility in eastern Kansas. This initiative expands Daxor's presence in Midwestern outpatient care, giving regional clinicians direct access to objective volume metrics.
Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas
Neutral
GlobeNewsWire
2 months ago
Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas
Daxor to Showcase How BVA Provides the Objective Plasma and Red Blood Cell Data Needed to Target Dysautonomia Therapy Oak Ridge, TN, July 07, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting for the first time at the 14th Annual Dysautonomia International Conference. Daxor will feature its FDA-cleared next-generation rapid, lightweight, lab-based Blood Volume Analyzer (BVA™).
Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas
Neutral
GlobeNewsWire
3 months ago
Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor
New Technology Expands Daxor's Diagnostic Capabilities to Enable Continuous, Remote Tracking of Blood Volume Status Using Wearable Sensors, Enhancing Care for Heart Failure, Syncope, Anemia, and Polycythemia OAK RIDGE, TN, June 02, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,635,917 B2, titled “Remote Blood Volume Monitor.
Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor
Neutral
GlobeNewsWire
4 months ago
Daxor Leverages MedAxiom CV Transforum Spring'26 to Accelerate Commercial Adoption of Blood Volume Analysis
Oak Ridge, TN, April 28, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will exhibit its Blood Volume Analyzer (BVA™) technology at the MedAxiom CV Transforum Spring'26 Conference. The event, being held at the Sawgrass Marriott Golf Resort & Spa, Ponte Vedra Beach, FL, from April 30 – May 2, 2026, is a premier venue for cardiovascular thought leaders and industry innovators to drive the future of cardiac care delivery.
Daxor Leverages MedAxiom CV Transforum Spring'26 to Accelerate Commercial Adoption of Blood Volume Analysis
Neutral
GlobeNewsWire
5 months ago
Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center
Oak Ridge, TN, April 08, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, continues its strategic expansion with the launch of a new BVA program at a premier cardiology facility in Southwest Ohio. This integration brings Daxor's state-of-the-art testing to a high-volume heart failure care setting, targeting the growing market for chronic disease management.
Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center
Neutral
GlobeNewsWire
5 months ago
Daxor's Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026
OAK RIDGE, TN, March 26, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces that new clinical data evaluating the accuracy of capillary leak detection scores compared to BVA was presented at the Society for Critical Care Medicine (SCCM) 2026 Critical Care Congress. The study, titled, "Mechanistic Specificity of Capillary Leak Indices: Validation in Heart Failure as a Negative Control," was featured during the Research Snapshot Theater.
Daxor's Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026
Neutral
GlobeNewsWire
5 months ago
Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions
Oak Ridge, TN, March 17, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces its participation as an exhibitor at the American College of Cardiology (ACC.26) Annual Scientific Session in New Orleans, LA, March 28–30, 2026. Daxor will showcase its new, rapid, portable Blood Volume Analyzer (BVA).
Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions
Neutral
Seeking Alpha
6 months ago
Daxor Corporation (DXR) Presents at IAccess Alpha Virtual Best Ideas Spring Investment Conference 2026 Prepared Remarks Transcript
Daxor Corporation (DXR) Presents at IAccess Alpha Virtual Best Ideas Spring Investment Conference 2026 Prepared Remarks Transcript
Daxor Corporation (DXR) Presents at IAccess Alpha Virtual Best Ideas Spring Investment Conference 2026 Prepared Remarks Transcript
Price charts implemented using Lightweight Charts™